SIRION Biotech custom engineers and manufactures viral vectors for R&D and preclinical testing. With this comprehensive service portfolio you gain access to all major gene delivery systems (Adeno-associated, Lentivirus and Adenovirus), offering suitable methods for close to any application, whether for in vitro or in vivo purposes.
Highest quality standards, solid experience in viral vector manufacturing and upscaling capabilities make SIRION Biotech an attractive partner for novel therapeutic development.
The SIRION Biotech custom virus portfolio includes:
AVV become a tool of choice for many preclinical in vivo and in vitro experiments and clinical studies in the field of cell and gene therapy. Ability to generate recombinant virus lacking viral genes but containing transgene, very low immunogenecity and long-term transgene expression makes adeno-associated viruses one of the safest and most common tools for clinical applications. Adeno-associated viruses (AVV) have linear single-stranded DNA (ssDNA) genome of approximately 4.5 kb, flanked by two inverted terminal repeats (ITR) and two open frames – rep and cap. Rep gene encodes regulatory proteins involved in genome replication (Rep 78/68) and packaging (Rep 52/408). Cap gene encodes 3 capsid proteins: VP1, VP2 and VP3 in a ratio of 10:1:1. Cap defines cell/tissue tropism. AVV are presented in various serotypes which express different tissue tropism. Based on this feature, certain serotypes are recommended when a specific tissue is planned to be targeted. Modifications of promoter or capsid allow to generate AAV which targets specific tissues or cells.
Lentiviruses are a type of retroviruses with a single stranded RNA genome. Lentiviruses have three main genes coding for the viral proteins: gag, pol, env responsible for viral capsid and matrix proteins (gag), viral integration and transcription of the carried transgene (pol), transmembrane proteins required for host cell entry (env). Lentiviral vectors are engineered based on lentiviruses including transgene flanked with LTRs. Lentivirus vectors contain only viral cis-regulatory elements necessary for genome integration, transcription and packaging of the vector RNA. All viral protein coding regions are removed providing space for insertion of foreign DNA. The total cloning capacity for transgene is 4–5 kb. Due to their ability to infect the broadest panel of cells of dividing and non-dividing cells, including primary cells, immortalized cell lines, hematopoietic stem cells, lentiviruses are widely used for generation of stable cell lines with gene expression or -knockdown and for CART cell generation.
Adenovirus vectors are non-toxic, non-integrating, non-enveloped viruses with a linear double-stranded DNA. Adenoviral vectors are based on Ad5 serotype. To enter the cells Ad5-based vectors use the Coxsackie-Adenovirus Receptor (CAR). To increase the packaging capacity in recombinant vectors two genes from the wild type adenovirus are deleted (E1 and E3): E1 is provided by the packaging cells (HEK293) and E3 is not essential for virus production. Deletion of E1 from the viral vector prevents the virus replication to guarantee the safety of adenoviral vector. Adenovirus vectors provide strong, transient gene expression or -knockdown are used for gene therapy, vaccine, and cancer therapy development.
With over 2000 projects under our belt we enable you to identify the best possible solution for your individual research and development project. We can discuss projects of all sizes, from standard virus production to GMP-ready scales.